Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) in Children

Acute graft-versus-host disease (aGVHD), a major obstacle to the success of allogeneic hematopoietic stem cell transplantation (HSCT) and affects 40 –60% of patients undergoing HSCT. GVHD is also a major cause of non-relapse mortality after HSCT. [1-3] Although the management of aGVHD has improved in recent years, [4] a therapeutic gap exists in effective management of aGVHD which is refractory to steroid therapy, particularly in subjects with more severe disease, determined by grade C/D, liver and lower gastrointestinal organ involvement and/or multi-organ involvement, or high risk stratification.

Source: Biology of Blood and Marrow Transplantation - February 6, 2020 Category: Hematology Authors: Joanne Kurtzberg, Susan Prockop, Sonali Chaudhury, Biljana Horn, Eneida Nemecek, Vinod Prasad, Prakash Satwani, Pierre Teira, Jack Hayes, Elizabeth Burke, for the MSB-275 Study Group Source Type: research